BR0311375A - Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero - Google Patents

Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero

Info

Publication number
BR0311375A
BR0311375A BR0311375-2A BR0311375A BR0311375A BR 0311375 A BR0311375 A BR 0311375A BR 0311375 A BR0311375 A BR 0311375A BR 0311375 A BR0311375 A BR 0311375A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
mammal
cognitive impairment
mild cognitive
treating dementia
Prior art date
Application number
BR0311375-2A
Other languages
English (en)
Inventor
Lars Lykke
Anders Gersel Pedersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29713304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0311375(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR0311375A publication Critical patent/BR0311375A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, USO DA MESMA, E, MéTODO PARA O TRATAMENTO DE DEMêNCIA OU DANO COGNITIVO SUAVE EM UM MAMìFERO". Uma composição farmacêutica compreendendo: (a) uma quantidade efetiva de um ou mais inibidores de acetilcolinesterase ou de um seu sal farmaceuticamente aceitável e (b) uma quantidade efetiva de um ou mais antagonistas de NMDA.
BR0311375-2A 2002-05-31 2003-05-22 Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero BR0311375A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31
PCT/DK2003/000342 WO2003101458A1 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
BR0311375A true BR0311375A (pt) 2005-03-15

Family

ID=29713304

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311375-2A BR0311375A (pt) 2002-05-31 2003-05-22 Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero

Country Status (17)

Country Link
EP (1) EP1509232B1 (pt)
JP (1) JP2005528431A (pt)
AT (1) ATE414519T1 (pt)
AU (1) AU2003227516B2 (pt)
BR (1) BR0311375A (pt)
CY (1) CY1108725T1 (pt)
DE (1) DE60324788D1 (pt)
DK (1) DK1509232T3 (pt)
ES (1) ES2314200T3 (pt)
IL (1) IL165255A0 (pt)
MX (1) MXPA04011762A (pt)
NO (1) NO332754B1 (pt)
NZ (1) NZ536603A (pt)
PL (1) PL373903A1 (pt)
PT (1) PT1509232E (pt)
SI (1) SI1509232T1 (pt)
WO (1) WO2003101458A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100777904B1 (ko) * 2002-10-24 2007-11-28 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
ATE486592T1 (de) * 2004-01-05 2010-11-15 Merz Pharma Gmbh & Co Kgaa Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer
AU2005205882A1 (en) * 2004-01-22 2005-08-04 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1740172A4 (en) * 2004-03-19 2007-10-10 Axonyx Inc ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER
EP1827385B1 (en) * 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
KR101213345B1 (ko) 2005-04-28 2012-12-17 에자이 알앤드디 매니지먼트 가부시키가이샤 항치매약을 함유하는 조성물
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
RU2414856C1 (ru) * 2009-12-01 2011-03-27 Государственное образовательное учреждение высшего профессионального образования Первый Московский медицинский университет имени И.М.Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития России) Способ определения эффективности противодементной терапии болезни альцгеймера
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2590696B1 (en) 2010-07-05 2017-03-08 Gambro Lundia AB An ambulatory ultrafiltration device, related methods and a computer program product
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2013160728A1 (en) * 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014055047A1 (en) * 2012-08-31 2014-04-10 Mahmut Bilgic Combination of idebenone and donezepil
WO2014035355A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Pharmaceutical combination comprising idebenone and memantine
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
GEP201706739B (en) * 2012-12-13 2017-09-25 H Lundbeck As Compositions comprising vortioxetine and donepezil
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP6629464B2 (ja) * 2016-05-18 2020-01-15 スヴェン・ライフ・サイエンシズ・リミテッド 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ
KR102592614B1 (ko) 2016-07-25 2023-10-24 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
US10548855B2 (en) * 2016-10-28 2020-02-04 Chase Pharmaceuticals Corporation Memantine combinations and use
TR201619184A2 (tr) 2016-12-22 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
DK3826639T3 (da) 2018-07-26 2024-09-23 Wista Lab Ltd Optimeret dosering af diaminophenothiaziner i populationer
PT3843702T (pt) 2019-05-31 2023-10-13 Tecnimede Soc Tecnico Medicinal Lda Combinação de dose fixa de libertação imediata de memantina e donepezilo

Also Published As

Publication number Publication date
NO332754B1 (no) 2013-01-07
MXPA04011762A (es) 2005-03-31
EP1509232B1 (en) 2008-11-19
JP2005528431A (ja) 2005-09-22
DE60324788D1 (de) 2009-01-02
CY1108725T1 (el) 2014-04-09
AU2003227516A1 (en) 2003-12-19
WO2003101458A1 (en) 2003-12-11
NO20045434L (no) 2004-12-13
DK1509232T3 (da) 2009-02-23
PT1509232E (pt) 2009-01-07
SI1509232T1 (sl) 2009-04-30
ATE414519T1 (de) 2008-12-15
AU2003227516B2 (en) 2008-03-20
ES2314200T3 (es) 2009-03-16
PL373903A1 (en) 2005-09-19
IL165255A0 (en) 2005-12-18
NZ536603A (en) 2007-06-29
EP1509232A1 (en) 2005-03-02

Similar Documents

Publication Publication Date Title
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
TR200100054T2 (tr) Paroksetin metansülfonat
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
BR9913752B1 (pt) uso de um produto para proteÇço de tecidos, e, processo para tratamento de tecidos.
AU2713500A (en) Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
PT1202724E (pt) Metodo para tratamento da dor cronica utilizando inibidores mek
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
NO20012058L (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
NO963506D0 (no) 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler
DE60010456D1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
PT1214936E (pt) Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
AP2003002743A0 (en) Therapeutic combination of a cept inhibitor and atorvastatin
ES2178157T3 (es) Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
BR9813684A (pt) Processo para tratar o glaucoma glc1a, e, composição para controlar o glaucoma glc1a.
NO981121D0 (no) Substituerte aminoforbindelser og deres anvendelse som analgetisk virksomme stoffer
AU2002214096A1 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
BR9811298A (pt) Uso de um composto de vanádio fisiologicamente aceitável
HU9503625D0 (en) Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema
NO20015257D0 (no) Farmasöytisk sammensetning for å hindre, behandle eller utviklingsinhibere enkel retinopati og preproliferativ retinopati

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.